Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 2,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719, tiotropium bromide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Jasper, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Medford, Oregon • Greenville, South Carolina • Spartanburg, South Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 42
States / cities: Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more

Conditions: Asthma
Interventions: FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI); Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444, tiotropium bromide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 10,355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 269
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Asthma
Interventions: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 36
States / cities: Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 31 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 33
States / cities: Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg); Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 9,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, UMEC, VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Newport Beach, California • San Diego, California • Upland, California + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol, Umeclidinium/ Vilanterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Hialeah, Florida • Baltimore, Maryland • St Louis, Missouri + 6 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 17
States / cities: Tucson, Arizona • Riverside, California • San Diego, California + 14 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Copd
Interventions: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI, TIO/OLO, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more

Search by objective public record fields.

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

VENTURI (VENTilation Using Respiratory Imaging)

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients